Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts. The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.
Study Type
OBSERVATIONAL
Enrollment
120
The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
Data from the ENMGs will be extracted from the cohort and analyzed.
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes
Lyon, France
Cranial nerves abnormality at clinical examination of abnormal ENMG
Data concerning the clinical examination and the ENMG will be extracted from the cohort of patients with neurological syndroms and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Centre de reference des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes".
Time frame: Immediately after diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.